Back to today’s briefing

Story perspectives

FDA Chief Faces Challenges Amid Biotech Stock Surge

4/25/2025

39 3

Summary

Story summary

Dr. Marty Makary's initial period as FDA commissioner is marked by hurdles from layoffs and restructuring, threatening to delay drug approvals and stifle innovation. He advocates for a streamlined process for rare disease treatments and stresses the importance of real-world data in ensuring vaccine safety. Amidst this, biotech stocks are climbing, fueled by tariff concerns and upcoming FDA decisions.

1 of 1

Story summary

Dr. Marty Makary's initial period as FDA commissioner is marked by hurdles from layoffs and restructuring, threatening to delay drug approvals and stifle innovation. He advocates for a streamlined process for rare disease treatments and stresses the importance of real-world data in ensuring vaccine safety. Amidst this, biotech stocks are climbing, fueled by tariff concerns and upcoming FDA decisions.